ADIPOGEN
LIVE

Serial Number

77636854

Owner

ADIPOGEN LIFE SCIENCES, INC.

Attorney

Rob G. Leach

First Use Date

Nov 1, 2009

Filing Date

Dec 19, 2008

Add to watchlist:

No watchlists yet
View on USPTO

ADIPOGEN Trademark

Serial Number: 77636854 • Registration: 4146965

ADIPOGEN is a trademark filed by ADIPOGEN LIFE SCIENCES, INC. on December 19, 2008. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

ADIPOGEN LIFE SCIENCES, INC. (4 trademarks)

9853 PACIFIC HEIGHTS BLVD.
SAN DIEGO, CA 92121

Entity Type: 03

AdipoGen Incorporation

Songdo TechnoPark 7-50 Songdo-dong
Yeonsu-gu Incheon 406-840 , KP

Entity Type: 03

Adipogen International, Inc. (2 trademarks)

11588 Sorrento Valley Road
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

December 19, 2008

Registration Date

May 22, 2012

First Use Anywhere

November 1, 2009

First Use in Commerce

November 1, 2009

Published for Opposition

July 14, 2009

Goods & Services

Biological preparations for medical purposes; Chemical reagents for medical or veterinary purposes; Diagnostic agents, preparations and substances for medical purposes; Diagnostic kits consisting primarily of polyclonal and monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Diagnostic reagents for medicinal use; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Medical diagnostic reagents; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of obesity and diabetes and inflammatory disorders, for use in angiogenesis, dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders [ ; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and natural medicinal extracts derived from animal, plant and microorganism sources for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, obesity and diabetes, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Reagents and media for medical and veterinary diagnostic purposes ]

Assays for research purposes; Biochemical proteins, enzymes and antibodies for scientific and medical research; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Biochemicals, namely, polypeptides for in vitro research use; Biochemicals, namely, polyclonal and monoclonal antibodies for in vitro scientific or research use; Biomedical compounds, namely, peptide substrates used in analyzing and detecting enzymes and proteins for laboratory or research use; Chemicals for use in the purification of proteins for in vitro use; Diagnostic kits for research and in vitro use consisting primarily of polyclonal and monoclonal antibodies, buffers [, and reagents ] to monitor proteins and reagents; Diagnostics, namely, diagnostic preparations and reagents other than for medical or veterinary purposes; Diagnostic preparations and reagents for scientific or research use; Diagnostic preparations and reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Protein arrays and nucleotide arrays for scientific and medical research; Reagent for chemical analyses; Reagents for scientific or medical research use; Reagents for use in scientific apparatus for chemical or biological analysis; Stem cells and stem cell reagents for research purposes; Testing kits containing peptide substrates used in analyzing and detecting proteins, enzymes and receptors for laboratory or research use; Testing kits containing peptide substrates used in analyzing and detecting proteins, enzymes and receptors for clinical or medical laboratory use

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
May 31, 2022 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
May 31, 2022 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
May 31, 2022 89AG
TEAS SECTION 8 & 9 RECEIVED
May 26, 2022 E89R
OFFICE ACTION ISSUED POU1
Sep 9, 2021 PUM1
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 9, 2021 APRE
TEAS SECTION 8 & 9 RECEIVED
Aug 24, 2021 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
May 22, 2021 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
May 24, 2018 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
May 24, 2018 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 24, 2018 APRE
TEAS SECTION 8 & 15 RECEIVED
May 10, 2018 E815
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 9, 2017 ASGN
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 22, 2017 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 12, 2014 ASGN
REGISTERED-PRINCIPAL REGISTER
May 22, 2012 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 17, 2012 SUNA
LAW OFFICE REGISTRATION REVIEW COMPLETED
Apr 16, 2012 REGV
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 13, 2012 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Mar 30, 2012 SUPC
USE AMENDMENT FILED
Mar 28, 2012 IUAF
TEAS STATEMENT OF USE RECEIVED
Mar 28, 2012 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 20, 2011 EXRA
SOU EXTENSION 4 GRANTED
Oct 19, 2011 EX4G
SOU EXTENSION 4 FILED
Oct 5, 2011 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 5, 2011 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 2, 2011 EXRA
SOU EXTENSION 3 GRANTED
Apr 1, 2011 EX3G
SOU EXTENSION 3 FILED
Mar 28, 2011 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 28, 2011 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 13, 2010 EXRA
ASSIGNED TO EXAMINER
Oct 13, 2010 DOCK
SOU EXTENSION 2 GRANTED
Oct 12, 2010 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 12, 2010 AITU
SOU EXTENSION 2 FILED
Sep 24, 2010 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 24, 2010 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 7, 2010 EXRA
SOU EXTENSION 1 GRANTED
Apr 5, 2010 EX1G
SOU EXTENSION 1 FILED
Apr 5, 2010 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 5, 2010 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 4, 2009 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 4, 2009 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 9, 2009 TCCA
NOA MAILED - SOU REQUIRED FROM APPLICANT
Oct 6, 2009 NOAM
PUBLISHED FOR OPPOSITION
Jul 14, 2009 PUBO
NOTICE OF PUBLICATION
Jun 24, 2009 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 9, 2009 PREV
ASSIGNED TO LIE
Jun 9, 2009 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2009 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 7, 2009 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 7, 2009 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 7, 2009 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 7, 2009 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 7, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 7, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 7, 2009 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2009 GNRN
NON-FINAL ACTION E-MAILED
Mar 22, 2009 GNRT
NON-FINAL ACTION WRITTEN
Mar 22, 2009 CNRT
ASSIGNED TO EXAMINER
Mar 14, 2009 DOCK
NOTICE OF PSEUDO MARK MAILED
Dec 24, 2008 MPMK
NEW APPLICATION ENTERED
Dec 23, 2008 NWAP